Osteoarthritis is a common form of arthritis causing damage to any joint, but usually impacts joints in our hands, hips, knees and spine affecting over 30 million people in the United States. We are currently trying to find ways to meet the medical needs for this condition by developing new types of treatments. Even though there is currently no cure, we have drugs for pain relief, but the challenge is that some of the commonly used drugs for osteoarthritis do not target the joint issues sufficiently. By focusing on the joint’s pharmacokinetics, it would be an essential key to deliver a more effective drug to the targeted points. With this in mind, the goal of MIT’s researcher, Brett Charles Gieger, is to prevent short periods of clearance from the drug by reducing the maximum concentration by providing low doses with high effect rather than repeated high doses with low effect. In one investigation, they have selected polyamidoamine (PANAM) dendrimers, man made compounds with particular properties, as the base nanomaterials in order to observe the interaction between the cartilage and nanomaterials. With electrostatic and biophysical components, PEG was used to calibrate the surface charge of the dendrimer for how it is known to improve biocompatibility of synthetics. Using mPEG13-NHS ester from Broadpharm combined with other solutions, they have concluded their PEGylated dendrimer system provides an accelerated generation and they have found that longer PEGs have significantly strong electrostatic interactions meaning that a high net charge of positively charged nanomaterials helps avoid joint clearance and provide a more sufficient concentration through the tissue. Until then, further studies are needed to investigate the interaction between the dendrimer regime and cartilage tissues. Thank you Brett Charles Geiger of MIT for this wonderful work.
Curious about our PEG Linkers? https://broadpharm.com/web/
#research #osteoarthritis #PEGLinkers #PEGsupply #PEGVendor #MIT